tert-butyl (R)-methyl(1-oxopropan-2- yl)carbamate | 130645-96-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl (R)-methyl(1-oxopropan-2- yl)carbamate
• 英文别名: tert-butyl (R)-methyl-N-(1-oxopropan-2-yl)carbamate；tert-butyl N-methyl-N-[(2R)-1-oxopropan-2-yl]carbamate
• CAS: 130645-96-4
• 化学式: C₉H₁₇NO₃
• 分子量: 187.239
• InChiKey: YGNLVHGLJDVIJS-SSDOTTSWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl (R)-methyl(1-oxopropan-2- yl)carbamate 在 三乙胺 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 20.0h， 生成 tert-butyl 3-((2R)-2-((tert-butoxycarbonyl)(methyl)amino)-1-((methylsulfonyl)oxy)propyl)-2-oxopyrrolidine-1-carboxylate
  参考文献：
  名称：

  [EN] LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2
  [FR] DÉRIVÉS DE PYRIMIDINE À FUSION HÉTÉROARYLE LACTAME SERVANT D'INHIBITEURS D'ERBB2

  摘要：

  本公开涉及抑制ErbB2的化合物及其组合物，包括突变形式的ErbB2，特别是那些携带Exon 20突变的形式，制备这些化合物和组合物的方法，以及它们在治疗或预防各种癌症方面的用途，如肺癌、胶质瘤、皮肤癌、头颈癌、唾液腺癌、乳腺癌、食管癌、肝癌、胃癌、子宫癌、宫颈癌、胆道癌、胰腺癌、结肠直肠癌、肾癌、膀胱癌或前列腺癌。

  公开号：

  WO2022140769A1
• 作为产物：
  描述：

  tert-butyl (R)-(1-hydroxypropan-2-yl)(methyl)carbamate 在 sodium hypochlorite 、 2,2,6,6-四甲基哌啶氧化物 、 碳酸氢钠 、 potassium bromide 作用下， 以 二氯甲烷 、 水 为溶剂， 生成 tert-butyl (R)-methyl(1-oxopropan-2- yl)carbamate
  参考文献：
  名称：

  [EN] FUSED TETRACYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2
  [FR] DÉRIVÉS DE QUINAZOLINE TÉTRACYCLIQUES FUSIONNÉS UTILISÉS EN TANT QU'INHIBITEURS D'ERBB2

  摘要：

  The present disclosure relates generally to compounds and compositions thereof for inhibition of ErbB2, including mutant forms of ErbB2, particularly those harboring an Exon 20 mutation, methods of preparing said compounds and compositions, and their use in the treatment or prophylaxis of various cancers, such as lung, glioma, skin, head neck, salivary gland, breast, esophageal, liver, stomach (gastric), uterine, cervical, biliary tract, pancreatic, colorectal, renal, bladder or prostate cancer.

  公开号：

  WO2023081637A1

文献信息

• Benzo[d]imidazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1)—Hit to Lead studies
  作者：Honghe Wan、Tram Huynh、Suhong Pang、Jieping Geng、Wayne Vaccaro、Michael A. Poss、George L. Trainor、Matthew V. Lorenzi、Marco Gottardis、Lata Jayaraman、Ashok V. Purandare

  DOI：10.1016/j.bmcl.2009.07.040

  日期：2009.9

  Hit to Lead optimization and SAR development led to the identification of the potent and selective benzo[d]imidazole inhibitor (17b) of Co-activator Associated Arginine Methyltransferase (CARM1).

  领先的优化和SAR的发展导致了共激活剂精氨酸甲基转移酶（CARM1）的有效和选择性苯并[ d ]咪唑抑制剂（17b）的鉴定。
• RACZKO, JERZY;GOLEBIOWSKI, ADAM;KRAJEWSKI, JANUSZ W.;GLUZINSKI, PRZEMYSLA+, TETRAHEDRON LETT., 31,(1990) N6, C. 3797-3800
  作者：RACZKO, JERZY、GOLEBIOWSKI, ADAM、KRAJEWSKI, JANUSZ W.、GLUZINSKI, PRZEMYSLA+

  DOI：——

  日期：——
• Stereoselective addition of furyllithium to variously N,N-diprotected d-alaninals
  作者：Jerzy Raczko、Adam Gołębiowski、Janusz W. Krajewski、Przemysław Gluziński、Janusz Jurczak

  DOI：10.1016/s0040-4039(00)97474-4

  日期：——
• [EN] METHODS OF USING MACROCYCLIC MODULATORS OF THE GHRELIN RECEPTOR<br/>[FR] PROCEDES D'UTILISATION DE MODULATEURS MACROCYCLIQUES DU RECEPTEUR DE LA GHRELINE
  申请人：TRANZYME PHARMA INC

  公开号：WO2006009645A1

  公开（公告）日：2006-01-26

  The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.
• [EN] LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2<br/>[FR] DÉRIVÉS DE PYRIMIDINE À FUSION HÉTÉROARYLE LACTAME SERVANT D'INHIBITEURS D'ERBB2
  申请人：ENLIVEN THERAPEUTICS INC

  公开号：WO2022140769A1

  公开（公告）日：2022-06-30

  The present disclosure relates generally to compounds and compositions thereof for inhibition of ErbB2, including mutant forms of ErbB2, particularly those harboring an Exon 20 mutation, methods of preparing said compounds and compositions, and their use in the treatment or prophylaxis of various cancers, such as lung, glioma, skin, head neck, salivary gland, breast, esophageal, liver, stomach (gastric), uterine, cervical, biliary tract, pancreatic, colorectal, renal, bladder or prostate cancer.

  本公开涉及抑制ErbB2的化合物及其组合物，包括突变形式的ErbB2，特别是那些携带Exon 20突变的形式，制备这些化合物和组合物的方法，以及它们在治疗或预防各种癌症方面的用途，如肺癌、胶质瘤、皮肤癌、头颈癌、唾液腺癌、乳腺癌、食管癌、肝癌、胃癌、子宫癌、宫颈癌、胆道癌、胰腺癌、结肠直肠癌、肾癌、膀胱癌或前列腺癌。